P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000890664.81647.d7 |
| _version_ | 1827332217074876416 |
|---|---|
| author | Lutz Van Heek Colin Stuka Helen Kaul Horst Müller Jasmin Mettler Felicitas Hitz Christian Baues Michael Fuchs Peter Borchmann Andreas Engert Markus Dietlein Conrad-Amadeus Voltin Carsten Kobe |
| author_facet | Lutz Van Heek Colin Stuka Helen Kaul Horst Müller Jasmin Mettler Felicitas Hitz Christian Baues Michael Fuchs Peter Borchmann Andreas Engert Markus Dietlein Conrad-Amadeus Voltin Carsten Kobe |
| author_sort | Lutz Van Heek |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:55:41Z |
| format | Article |
| id | doaj.art-1d7597a96fe5418d95f3bb03f8861aaf |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:55:41Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1d7597a96fe5418d95f3bb03f8861aaf2024-03-03T04:22:33ZengWileyHemaSphere2572-92412022-10-016121210.1097/01.HS9.0000890664.81647.d7202210005-00024P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 TrialLutz Van Heek0Colin Stuka1Helen Kaul2Horst Müller3Jasmin Mettler4Felicitas Hitz5Christian Baues6Michael Fuchs7Peter Borchmann8Andreas Engert9Markus Dietlein10Conrad-Amadeus Voltin11Carsten Kobe121 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany3 Swiss Group for Clinical Cancer Research, Bern Switzerland5 Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000890664.81647.d7 |
| spellingShingle | Lutz Van Heek Colin Stuka Helen Kaul Horst Müller Jasmin Mettler Felicitas Hitz Christian Baues Michael Fuchs Peter Borchmann Andreas Engert Markus Dietlein Conrad-Amadeus Voltin Carsten Kobe P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial HemaSphere |
| title | P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial |
| title_full | P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial |
| title_fullStr | P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial |
| title_full_unstemmed | P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial |
| title_short | P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial |
| title_sort | p024 predictive value of baseline metabolic tumor volume in early stage favorable hodgkin lymphoma data from the prospective multicenter phase iii hd16 trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000890664.81647.d7 |
| work_keys_str_mv | AT lutzvanheek p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT colinstuka p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT helenkaul p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT horstmuller p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT jasminmettler p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT felicitashitz p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT christianbaues p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT michaelfuchs p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT peterborchmann p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT andreasengert p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT markusdietlein p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT conradamadeusvoltin p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT carstenkobe p024predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial |